WO2021212360A1 - Traitement d'un diabète non traité ou résistant au traitement au moyen d'un activateur de glucokinase et d'un inhibiteur du cotransporteur de sodium-glucose de type 2 - Google Patents

Traitement d'un diabète non traité ou résistant au traitement au moyen d'un activateur de glucokinase et d'un inhibiteur du cotransporteur de sodium-glucose de type 2 Download PDF

Info

Publication number
WO2021212360A1
WO2021212360A1 PCT/CN2020/086100 CN2020086100W WO2021212360A1 WO 2021212360 A1 WO2021212360 A1 WO 2021212360A1 CN 2020086100 W CN2020086100 W CN 2020086100W WO 2021212360 A1 WO2021212360 A1 WO 2021212360A1
Authority
WO
WIPO (PCT)
Prior art keywords
less
diabetes
inhibitor
treatment
resistant
Prior art date
Application number
PCT/CN2020/086100
Other languages
English (en)
Inventor
Li Chen
Shuang REN
Jiayi Zhang
Original Assignee
Hua Medicine (Shanghai) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hua Medicine (Shanghai) Ltd. filed Critical Hua Medicine (Shanghai) Ltd.
Priority to PCT/CN2020/086100 priority Critical patent/WO2021212360A1/fr
Priority to AU2020443475A priority patent/AU2020443475A1/en
Priority to CA3181882A priority patent/CA3181882A1/fr
Publication of WO2021212360A1 publication Critical patent/WO2021212360A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement, de prévention ou d'atténuation d'un ou de plusieurs symptômes d'un diabète non traité ou résistant au traitement faisant appel à un activateur de glucokinase et un inhibiteur du cotransporteur de sodium-glucose de type 2.
PCT/CN2020/086100 2020-04-22 2020-04-22 Traitement d'un diabète non traité ou résistant au traitement au moyen d'un activateur de glucokinase et d'un inhibiteur du cotransporteur de sodium-glucose de type 2 WO2021212360A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CN2020/086100 WO2021212360A1 (fr) 2020-04-22 2020-04-22 Traitement d'un diabète non traité ou résistant au traitement au moyen d'un activateur de glucokinase et d'un inhibiteur du cotransporteur de sodium-glucose de type 2
AU2020443475A AU2020443475A1 (en) 2020-04-22 2020-04-22 Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
CA3181882A CA3181882A1 (fr) 2020-04-22 2020-04-22 Traitement d'un diabete non traite ou resistant au traitement au moyen d'un activateur de glucokinase et d'un inhibiteur du cotransporteur de sodium-glucose de type 2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/086100 WO2021212360A1 (fr) 2020-04-22 2020-04-22 Traitement d'un diabète non traité ou résistant au traitement au moyen d'un activateur de glucokinase et d'un inhibiteur du cotransporteur de sodium-glucose de type 2

Publications (1)

Publication Number Publication Date
WO2021212360A1 true WO2021212360A1 (fr) 2021-10-28

Family

ID=78270929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/086100 WO2021212360A1 (fr) 2020-04-22 2020-04-22 Traitement d'un diabète non traité ou résistant au traitement au moyen d'un activateur de glucokinase et d'un inhibiteur du cotransporteur de sodium-glucose de type 2

Country Status (3)

Country Link
AU (1) AU2020443475A1 (fr)
CA (1) CA3181882A1 (fr)
WO (1) WO2021212360A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264445A1 (en) * 2008-04-16 2009-10-22 Steven Joseph Berthel Pyrrolidinone glucokinase activators
WO2012006398A2 (fr) * 2010-07-09 2012-01-12 Bhv Pharma, Inc. Système d'administration à libération immédiate/retardée en combinaison pour des médicaments à courte demi-vie comprenant de la rémogliflozine
US20150315176A1 (en) * 2012-12-25 2015-11-05 Hua Medicine Process for the Preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine
WO2018030879A1 (fr) * 2016-08-12 2018-02-15 주식회사 노브메타파마 Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
WO2019228362A1 (fr) * 2018-05-31 2019-12-05 华领医药技术（上海）有限公司 Combinaison et composition pharmaceutiques, et préparation combinée contenant un activateur de glucokinase et un médicament hypoglycémiant à base de biguanide, ainsi que leur procédé de préparation et leur utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264445A1 (en) * 2008-04-16 2009-10-22 Steven Joseph Berthel Pyrrolidinone glucokinase activators
WO2012006398A2 (fr) * 2010-07-09 2012-01-12 Bhv Pharma, Inc. Système d'administration à libération immédiate/retardée en combinaison pour des médicaments à courte demi-vie comprenant de la rémogliflozine
US20150315176A1 (en) * 2012-12-25 2015-11-05 Hua Medicine Process for the Preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine
WO2018030879A1 (fr) * 2016-08-12 2018-02-15 주식회사 노브메타파마 Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
WO2019228362A1 (fr) * 2018-05-31 2019-12-05 华领医药技术（上海）有限公司 Combinaison et composition pharmaceutiques, et préparation combinée contenant un activateur de glucokinase et un médicament hypoglycémiant à base de biguanide, ainsi que leur procédé de préparation et leur utilisation
CN110548148A (zh) * 2018-05-31 2019-12-10 华领医药技术（上海）有限公司 含有葡萄糖激酶激活剂和sglt-2抑制剂的药物组合及其制备方法和用途

Also Published As

Publication number Publication date
CA3181882A1 (fr) 2021-10-28
AU2020443475A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US20190175544A1 (en) Pharmaceutical Compositions and Methods for Countering Chemotherapy Induced Cardiotoxicity
BRPI1008560B1 (pt) Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
JP2008509145A (ja) 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
AU2021244918A1 (en) Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
CN111372930A (zh) 一种SGLTs抑制剂及其应用
CA2598491A1 (fr) Diastereoisomeres de of 4-hydroxyisoleucine et utilisations associees
US11872221B2 (en) Treating untreated or treatment-resistant diabetes with glucokinase activator
WO2021243645A1 (fr) Activateur de glucokinase pour le traitement d'un diabète avec insuffisance rénale
WO2021151251A1 (fr) Traitement du diabète résistant à un traitement avec un activateur de glucokinase
US20210244715A1 (en) Gpx4 inhibitor in combination with anticancer agent for treating proliferative disease
US11813274B2 (en) Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
WO2021212360A1 (fr) Traitement d'un diabète non traité ou résistant au traitement au moyen d'un activateur de glucokinase et d'un inhibiteur du cotransporteur de sodium-glucose de type 2
US11857536B2 (en) Glucokinase activator for treating diabetes with renal impairment
TW201720443A (zh) 用以治療帕金森氏症之經氘化左旋多巴、碳度巴、以及奧匹卡朋的組合
WO2021243646A1 (fr) Activateur de glucokinase pour le traitement du diabète à insuffisance hépatique
CN106749228A (zh) 一种小檗碱药物及其制备方法与应用
US6531461B1 (en) Medicament for the treatment of diabetes
US20190231787A1 (en) Methods and compounds for treating alcohol use disorders and associated diseases
EP4104833B1 (fr) Acide ascorbique et quinone pour le traitement du cancer
WO2023165382A1 (fr) Utilisation d'un composé d'acyltadine ayant une activité inhibitrice de glycosidase
TW202140460A (zh) 吡唑基嘧啶及其用途
EP4313053A1 (fr) Pyrazolylpyrimidines pour le traitement d'une tumeur solide maligne
WO2024026012A1 (fr) Compositions et méthodes pour le traitement de troubles métaboliques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20932551

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3181882

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020443475

Country of ref document: AU

Date of ref document: 20200422

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20932551

Country of ref document: EP

Kind code of ref document: A1